Financial Improvement for Aton in 2024

Aton Group, a medical sciences company, has published its consolidated results for the 2024 financial year, revealing a significant improvement in its net profit and a strengthening of its equity. Thanks to a successful financial restructuring, including a €3.6 million capital increase, the company significantly reduced its debt, achieving positive equity of €0.8 million. This restructuring also resulted in a drastic reduction in operating expenses of 38%.

Although revenue remained stable at €0.6 million, net loss was divided by seven, from -€7.9 million in 2023 to -€1.1 million in 2024. Aton plans to increase its revenue in 2025 by optimizing its operations and expanding its subsidiaries, particularly by strengthening the production and marketing of its diagnostic solutions.